hsa-mir-3665: Hsa-mir-3665 is a miRNA that has been mentioned multiple times in the provided text. It is one of the most representative miRNAs, along with hsa-let-7c-5p, hsa-miR-181a-5p, and hsa-miR-7704 [PMC9818028]. It has been found to be up-regulated in team A [PMC4222264], team B [PMC4222264], and VP [PMC4865051]. Additionally, hsa-mir-3665 is one of the top 10 PLK1 mRNA-targeting miRNAs [PMC9811677]. The differential abundance of hsa-mir-3665 has been validated in Parkinson's disease patients compared to healthy controls [PMC8065836]. It has also been reported as a seldom mentioned miRNA [PMC6571392]. Hsa-mir-3665 was used in transient transfection experiments with SiHa and CaSki cells [PMC5190061], and its methylation was found to be absent in most samples but increased in SCCs [PMC5190061]. Furthermore, it was down-regulated by 5-10-fold along with other miRNAs (hsa-miR-199a-2, hsa-miR410, hsa-miR487-b) within a miRNA family [PMC4320460]. Hsa-mir-3665 was also found to exhibit regulation during wound healing experiments using HDFa cells [PMC8876102], and its expression was comparatively high along with other miRNAs (hsa-miR3960, hsa-miR1469) within a cluster of miRNAs. Finally, it has been assigned the name "hsa-mir3665" in the miRBase database[ PMC2886071].